Clinical Trial Update: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion [Phase 2]

View source ↗

Summary

Phase 2 multicenter study evaluating ibrutinib in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletion; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion | Phase 2 | Status: COMPLETED | Results posted: 2015-06-09